These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24378862)

  • 61. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project.
    Helander A; Bäckberg M; Hultén P; Al-Saffar Y; Beck O
    Forensic Sci Int; 2014 Oct; 243():23-9. PubMed ID: 24726531
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.
    Kikura-Hanajiri R; Kawamura NU; Goda Y
    Drug Test Anal; 2014; 6(7-8):832-9. PubMed ID: 24573957
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The impact of Australian legislative changes on synthetic cannabinoid exposures reported to the New South Wales Poisons Information Centre.
    Cairns R; Brown JA; Gunja N; Buckley NA
    Int J Drug Policy; 2017 May; 43():74-82. PubMed ID: 28343112
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Newly Emerging Drugs of Abuse and Their Detection Methods: An ACLPS Critical Review.
    Liu L; Wheeler SE; Venkataramanan R; Rymer JA; Pizon AF; Lynch MJ; Tamama K
    Am J Clin Pathol; 2018 Jan; 149(2):105-116. PubMed ID: 29385414
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Detection and quantification of new designer drugs in human blood: Part 2 - Designer cathinones.
    Ammann D; McLaren JM; Gerostamoulos D; Beyer J
    J Anal Toxicol; 2012 Jul; 36(6):381-9. PubMed ID: 22593565
    [TBL] [Abstract][Full Text] [Related]  

  • 66. New drugs of abuse in North America.
    Haroz R; Greenberg MI
    Clin Lab Med; 2006 Mar; 26(1):147-64, ix. PubMed ID: 16567229
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Doors of deception: the diaspora of designer drugs.
    Kerwin J
    Drug Test Anal; 2011 Sep; 3(9):527-31. PubMed ID: 21960538
    [No Abstract]   [Full Text] [Related]  

  • 68. Synthetic drugs: bath salts and spice.
    Randolph SA
    Workplace Health Saf; 2014 Feb; 62(2):88. PubMed ID: 24512723
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Emerging trends in the abuse of designer drugs and their catastrophic health effects: update on chemistry, pharmacology, toxicology and addiction potential.
    Rapaka RS; Purohit V; Schnur P; Rutter J
    Life Sci; 2014 Feb; 97(1):1. PubMed ID: 24529194
    [No Abstract]   [Full Text] [Related]  

  • 70. Detection of synthetic cannabinoids in oral fluid using ELISA and LC-MS-MS.
    Rodrigues WC; Catbagan P; Rana S; Wang G; Moore C
    J Anal Toxicol; 2013 Oct; 37(8):526-33. PubMed ID: 23946452
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports.
    Miotto K; Striebel J; Cho AK; Wang C
    Drug Alcohol Depend; 2013 Sep; 132(1-2):1-12. PubMed ID: 23916320
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Metabolism and toxicological analysis of synthetic cannabinoids in biological fluids and tissues.
    Presley BC; Gurney SM; Scott KS; Kacinko SL; Logan BK
    Forensic Sci Rev; 2016 Jul; 28(2):103-69. PubMed ID: 27257717
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthetic cannabinoid and cathinone use among US soldiers.
    Berry-Cabán CS; Kleinschmidt PE; Rao DS; Jenkins J
    US Army Med Dep J; 2012; ():19-24. PubMed ID: 23007932
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A 9-state analysis of designer stimulant, "bath salt," hospital visits reported to poison control centers.
    Warrick BJ; Hill M; Hekman K; Christensen R; Goetz R; Casavant MJ; Wahl M; Mowry JB; Spiller H; Anderson D; Aleguas A; Gummin D; Thomas R; Nezlek C; Smolinske S
    Ann Emerg Med; 2013 Sep; 62(3):244-51. PubMed ID: 23540815
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Synthetic Cannabinoids and Cathinones: Prevalence and Markets.
    Bretteville-Jensen AL; Tuv SS; Bilgrei OR; Fjeld B; Bachs L
    Forensic Sci Rev; 2013 Mar; 25(1-2):7-26. PubMed ID: 26226848
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Rave drugs: pharmacological considerations.
    Klein M; Kramer F
    AANA J; 2004 Feb; 72(1):61-7. PubMed ID: 15098519
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emergence of new classes of recreational drugs-synthetic cannabinoids and cathinones.
    Khullar V; Jain A; Sattari M
    J Gen Intern Med; 2014 Aug; 29(8):1200-4. PubMed ID: 24553958
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Synthetic cathinones ("bath salts").
    Banks ML; Worst TJ; Rusyniak DE; Sprague JE
    J Emerg Med; 2014 May; 46(5):632-42. PubMed ID: 24565885
    [TBL] [Abstract][Full Text] [Related]  

  • 80. ["Legal highs" from the German internet--"bath salt drugs" on the rise].
    Musshoff F; Hottmann L; Hess C; Madea B
    Arch Kriminol; 2013; 232(3-4):91-103. PubMed ID: 24358620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.